<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="0" ids="16990">Bilirubin</z:chebi> has <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and anti-inflammatory activities </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies demonstrated that higher <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels were associated with reduced prevalence of <z:hpo ids='HP_0004950'>peripheral arterial disease</z:hpo> (PAD) </plain></SENT>
<SENT sid="2" pm="."><plain>However, the relationship between <z:chebi fb="0" ids="16990">bilirubin</z:chebi> and lower-limb <z:mpath ids='MPATH_686'>amputation</z:mpath>, a consequence of PAD, is currently unknown </plain></SENT>
<SENT sid="3" pm="."><plain>We hypothesised that, in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:chebi fb="0" ids="16990">bilirubin</z:chebi> concentrations may inversely associate with lower-limb <z:mpath ids='MPATH_686'>amputation</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: The relationship between baseline plasma total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels and <z:mpath ids='MPATH_686'>amputation</z:mpath> events was analysed in 9,795 type 2 diabetic patients from the <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> Intervention and Event Lowering in <z:mp ids='MP_0002055'>Diabetes</z:mp> (FIELD) study </plain></SENT>
<SENT sid="5" pm="."><plain>The analysis plan was pre-specified </plain></SENT>
<SENT sid="6" pm="."><plain>Lower-limb <z:mpath ids='MPATH_686'>amputation</z:mpath> was adjudicated blinded to treatment allocation </plain></SENT>
<SENT sid="7" pm="."><plain>Relevant clinical and biochemical data were available for analyses </plain></SENT>
<SENT sid="8" pm="."><plain><z:mpath ids='MPATH_686'>Amputation</z:mpath> was a pre-specified tertiary endpoint </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: <z:chebi fb="0" ids="16990">Bilirubin</z:chebi> concentrations were significantly inversely associated with lower-limb <z:mpath ids='MPATH_686'>amputation</z:mpath>, with a greater than threefold risk gradient across levels </plain></SENT>
<SENT sid="10" pm="."><plain>Individuals with lower <z:chebi fb="0" ids="16990">bilirubin</z:chebi> concentrations had a higher risk for first <z:mpath ids='MPATH_686'>amputation</z:mpath> (HR 1.38 per 5 μmol/l decrease in <z:chebi fb="0" ids="16990">bilirubin</z:chebi> concentration, 95% CI 1.07, 1.79, p = 0.013) </plain></SENT>
<SENT sid="11" pm="."><plain>The same association persisted after adjustment for baseline variables, including age, height, smoking status, γ-glutamyltransferase level, HbA, trial treatment allocation (placebo vs <z:chebi fb="0" ids="5001">fenofibrate</z:chebi>), as well as previous PAD, non-PAD <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, <z:mpath ids='MPATH_686'>amputation</z:mpath> or diabetic <z:hpo ids='HP_0200042'>skin ulcer</z:hpo>, <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, <z:hpo ids='HP_0000112'>nephropathy</z:hpo> and diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> (HR 1.38 per 5 μmol/l decrease in <z:chebi fb="0" ids="16990">bilirubin</z:chebi> concentration, 95% CI 1.05, 1.81, p = 0.019) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS/INTERPRETATION: Our results identify a significant inverse relationship between <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels and total lower-limb <z:mpath ids='MPATH_686'>amputation</z:mpath>, driven by major <z:mpath ids='MPATH_686'>amputation</z:mpath> </plain></SENT>
<SENT sid="13" pm="."><plain>Our data raise the hypothesis that <z:chebi fb="0" ids="16990">bilirubin</z:chebi> may protect against <z:mpath ids='MPATH_686'>amputation</z:mpath> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>